Application of cardiopulmonary bypass during extended resection of locally advanced lung cancer  LIAO Xiang-li, FAN Shizhi, LI Zhiping, CHEN Jianming, NIU Huijun, HE Yong, HU Yijie. Department of Thoracic Surgery, Daping Hospital, The Third Military Medical University, Chongqing 400042, P. R. China

Corresponding author : FAN Shizhi. E-mail : fanszh@yahoo.com.cn

【Abstract】Background and objective  Locally advanced lung cancer includes III A and III B lung cancer that tumors are localized within the chest and with no clinic and pathologic distal metastasis. In this study the results of extended resection of a portion of heart or great vessels with cardiopulmonary bypass was summarized in the treatment of locally advanced lung cancer. Methods  Lobectomy or pneumonectomy combined with extended partial excision of the heart or great vessels were carried out in 10 patients with locally advanced lung cancer. The operations included aortic resection and reconstruction with left heart bypass in 2 cases, extended resection of left atrium with normal cardiopulmonary bypass in 5 cases, and resection and reconstruction of superior vena cava in 3 cases respectively. Results  The patients had no operative complication except for one haemotherax, which was controlled by re-exploration. One patient died of brain metastasis 6 months after operation and another one died of multiple metastasis 26 months after operation. The others were alive. Conclusion  CPB is a safe and effective anesthetic procedure during extended resection of locally advanced lung cancer although it is controversial for aggravating operative trauma, complex technique and high cost.

【Key words】Cardiopulmonary bypass Locally advanced lung cancer Resection and reconstruction
1.2 发现例仍存活死亡示窦性心律超过采用并行体循环

1.3

1.3.1 Delphin II

1.3.2

2

3
The 3rd Pan Pacific International Lung Cancer Conference
held in conjunction with The 3rd China North and South Lung Cancer Summit

Time and location: October 12-15, 2006
Shanghai International Conference Center
Shanghai, China

Conference Chairmen: Shujun Cheng, M. D., Professor
   David Gandara, M. D., Professor of Medicine
   David M. Jablons, M. D., Professor of Surgery
   Yan Sun, M. D., Professor
   Nanshan Zhong, M. D., Professor
   Xiuyi Zhi, M. D., Professor

Conference overview
This conference is designed to update practicing oncologists and thoracic surgeons both in China and worldwide on recent advances in the management of lung cancer, including those advances reported at the 42nd Annual Meeting of the American Society of Clinical Oncology held in Atlanta, GA, USA, in June 2006. The conference will detail current data on the use of targeted agents to treat non-small-cell lung cancer (NSCLC). Updates on chemotherapy regimens for both early-stage and advanced NSCLC will be presented. Unique approaches and challenges to treating lung cancer in China and the rest of Asia will also be discussed as well as the integration of lung cancer research between China and other parts of the world. Each session will include ample time for questions and answers for the audience and the presenting faculty.

CME Accreditation and Credit Designation
Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Contact: By E-mail: CME@pergrouplp.com
   By Fax: 214-367-3305
   By Mail: Physicians’ Education Resource

ATTN: CME Department
3500 Maple Avenue, Suite 700
Dallas, TX 75219
By Phone: 888-949-0045
For further information and registration please visit: http://www.CancerConferences.com